Analyst Research and Ratings: ADMA Biologics, Inc. (ADMA), Lightbridge Corporation (LTBR)

ADMA Biologics, Inc. (NASDAQ:ADMA) tinted gains of +1.03% (+0.04 points) to US$3.93. The volume of 0.39 Million shares climbed down over an trading activity of 484.9 Million shares. EPS ratio determined by looking at last 12 month figures is -1.42. Over the same time span, the stock marked US$6.96 as its best level and the lowest price reached was US$2.08. The corporation has a market cap of US$179.44 Million.

ADMA Biologics, Inc. (NASDAQ:ADMA)’s earnings per share has been growing at a -6.6 percent rate over the past 5 year when average revenue increase was noted as 82.7 percent. The return on equity ratio or ROE stands at -159.4 percent while most common profitability ratio return on investment (ROI) was -48.6 percent. The company’s institutional ownership is monitored at 57.7 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses -72.4 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.86. 6 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Lightbridge Corporation (NASDAQ:LTBR) is worth US$19.41 Million and has recently risen 1.03% to US$0.61. The latest exchange of 0.32 Million shares is below its average trading activity of 206.05 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$1.52 while the mean 12-month price target for the shares is US$10.5.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.67, and a price to sales ratio of 1866.65. For the past 5 years, the company’s revenue has grown -45.6%, while the company’s earnings per share has grown 15.3%. With an institutional ownership near 5.7%, it carries an earnings per share ratio of -0.78.